Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Prelude Therapeutics Inc | prld-ex322_6.htm |
| EX-31.2 - EX-31.2 - Prelude Therapeutics Inc | prld-ex312_8.htm |
| EX-31.1 - EX-31.1 - Prelude Therapeutics Inc | prld-ex311_9.htm |
| EX-3.2 - EX-3.2 - Prelude Therapeutics Inc | prld-ex32_235.htm |
| EX-3.1 - EX-3.1 - Prelude Therapeutics Inc | prld-ex31_234.htm |
| 10-Q - 10-Q - Prelude Therapeutics Inc | prld-10q_20200930.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Krishna Vaddi, Chief Executive Officer of Prelude Therapeutics Incorporated (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
|
|
(1) |
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
(2) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: November 10, 2020 |
|
By: |
/s/ Krishna Vaddi |
|
|
|
|
Krishna Vaddi, PhD |
|
|
|
|
Chief Executive Officer (Principal Executive Officer) |